EGRX Projected Dividend Yield
Eagle Pharmaceuticals, Inc. ( OTCBB : EGRX )Eagle Pharmaceuticals is an integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. Co.'s products and product portfolio include: BARHEMSYS® (amisulpride for injection), which is for the treatment of postoperative nausea and vomiting; BYFAVO® (remimazolam for injection), which is indicated for the induction and maintenance of procedural sedation; bendamustine ready-to-dilute (RTD) 500ml solution, infused bendamustine RTD, and bendamustine RTD and infused RTD in Japan for Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma; Ryanodex® (dantrolene sodium) for Malignant Hyperthermia; and EA-114 (fulvestrant) for breast cancer. 20 YEAR PERFORMANCE RESULTS |
EGRX Dividend History Detail EGRX Dividend News EGRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |